HC Wainwright Reaffirms “Buy” Rating for VYNE Therapeutics (NASDAQ:VYNE)

Posted by Latisha Jones on May 9th, 2024

HC Wainwright restated their buy rating on shares of VYNE Therapeutics (NASDAQ:VYNE – Free Report) in a research note published on Monday, Benzinga reports. They currently have a $5.75 price target on the stock.

VYNE Therapeutics Trading Down 5.9 %

VYNE stock opened at $2.72 on Monday. The company has a market capitalization of $38.35 million, a P/E ratio of -0.39 and a beta of 1.26. VYNE Therapeutics has a twelve month low of $1.67 and a twelve month high of $8.73. The firm has a 50 day simple moving average of $2.51 and a 200-day simple moving average of $2.59.

VYNE Therapeutics (NASDAQ:VYNE – Get Free Report) last announced its quarterly earnings data on Thursday, February 29th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.30. VYNE Therapeutics had a negative return on equity of 77.46% and a negative net margin of 6,710.38%. The firm had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.15 million. On average, research analysts predict that VYNE Therapeutics will post -1 EPS for the current year.

Institutional Investors Weigh In On VYNE Therapeutics

An institutional investor recently bought a new position in VYNE Therapeutics stock. Eventide Asset Management LLC bought a new stake in VYNE Therapeutics Inc. (NASDAQ:VYNE – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 1,394,336 shares of the company’s stock, valued at approximately $3,249,000. Eventide Asset Management LLC owned 9.99% of VYNE Therapeutics as of its most recent SEC filing. 83.78% of the stock is currently owned by hedge funds and other institutional investors.

VYNE Therapeutics Company Profile

(Get Free Report)

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.